Business Wire

Current Chemicals Expands U.S. Production of Rare-Earth Fluorides With New Investment From Momentum Global Ventures

5.11.2026 15:14:00 EET | Business Wire | Press release

Share

Current Chemicals, Inc. (“CCI”), one of the few U.S. companies converting separated rare-earth oxides into the fluorides used to make rare-earth metals and magnets, today announced an additional investment from its lead shareholder, Momentum Global Ventures (“MGV”). The investment will significantly increase CCI’s production of neodymium fluoride, dysprosium fluoride, and other key rare-earth fluorides in Cleveland.

The funding adds infrastructure, equipment and engineering staff for fluorides of neodymium, dysprosium, terbium, gadolinium, yttrium, scandium, lanthanum, and lithium for reducing light rare-earths to metal: key inputs for permanent magnets, advanced coatings, and alloys.

Neodymium fluoride and dysprosium fluoride are key feedstocks for the metal at the core of high-performance magnets in electric motors, wind turbines and defense systems. Most processing capacity today is in China and, with U.S. defense sourcing rules tightening from January 2027, domestic conversion is one of the scarcest links in America’s mine-to-magnet supply chain.

“Demand for these fluorides is accelerating as upstream rare-earth supply expands and downstream magnet, coating, and alloy production grows, and this investment lets us scale quickly using the infrastructure and process expertise we already have in Cleveland,” said Bill Cohen, Ph.D., CEO & Chairman of Current Chemicals. “This added volume is an important step toward our goal of 1,000 metric tons of annual capacity and beyond. Momentum Global Ventures shares our vision of building a reliable, high-quality source of these critical materials for a resilient supply chain serving manufacturers across North America and Europe.”

“The world needs these critical materials, and demand is enormous,” said Pieter Six, Asset Director at Momentum Global Ventures and CCI board member. “Investing again shows our long-term commitment to CCI and to a secure domestic supply chain”.

About Current Chemicals

Current Chemicals, Inc. is a Cleveland-based specialty chemicals and materials manufacturer with more than 75 years on its Ivanhoe Road site, originally as part of General Electric. It produces rare-earth fluorides, high-purity specialty chemicals and LED phosphors for defense, aerospace, semiconductor, and lighting customers.

Visit currentchemicals.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105393088/en/

Contacts

Media contact:
Bill Cohen
info@currentchemicals.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

iConnections and Preqin, a Part of BlackRock, Announce Collaboration to Bring Institutional Data to Violet, an AI-Powered Capital Introduction Platform5.11.2026 15:00:00 EET | Press release

iConnections today announced a collaboration with Preqin, a part of BlackRock, that brings one of the industry's leading sources of private markets data and intelligence— spanning fund managers, institutional investors, funds, benchmarks and indices— to Violet, iConnections' AI-powered capital introduction platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105840622/en/ Preqin's data is now inside Violet Powered by Preqin, the integration gives Global Alts attendees access to a broader network of institutional alternatives market participants, inside the same platform where thousands of allocators and managers already discover one another, book meetings and build relationships. “Alternative investing has always been driven by relationships, but the next chapter will be driven by relationships informed by better data,” said Ron Biscardi, CEO of iConnections. “Bringing Preqin's institutional intelligence into iConnect

SLB OneSubsea Awarded Contract for Lyra Field Development Offshore Norway5.11.2026 14:49:00 EET | Press release

Global energy technology company SLB (NYSE: SLB) today announced that its OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104799196/en/ The SLB (NYSE: SLB) OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). Building on nearly a decade of collaboration through Aker BP’s alliance model, Aker BP and SLB OneSubsea worked together from the early stages of the project to shape the development strategy for Lyra. The field will be developed as a subsea tieback to existing infrastructure using proven, standardi

EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) Sign an Agreement to Pool Their Expertise in Advanced Autonomous Underwater Technologies.5.11.2026 13:48:00 EET | Press release

The Technology Innovation Institute, the applied-research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has signed an agreement with Naval Group, a global leader in naval defense, to advance cooperation in autonomous underwater technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105684133/en/ EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) sign an agreement to pool their expertise in advanced autonomous underwater technologies. (Photo: AETOSWire) Announced during Euronaval 2026, the collaboration will focus on exploring opportunities for the joint development and commercialization of uncrewed underwater vehicles. The ambition is to deliver advanced autonomous solutions for persistent maritime surveillance and underwater reconnaissance for operations in non-contested waters, in addition to the ambition of delivering combat UUV for operations in contested waters. A key are

Sugar Taxes Under Scrutiny: New Competere Study Questions Health Outcomes and Warns of Unintended Consequences5.11.2026 13:00:00 EET | Press release

As governments debate sugar taxation and nutrition measures, a new policy paper asks a critical question: Do these interventions deliver lasting health improvements, for whom, and at what cost? Published by Competere with the support of the Association of Latin American Sugar Producers (UNALA), Understanding Sugar Beyond the Narrative – by Pietro Paganini – offers policymakers, journalists, and consumers an accessible guide to sugar’s role in health, sustainability, and the global economy. Combining scientific evidence with economic and policy analysis, the paper challenges common misconceptions and examines whether taxation, warning labels, and reformulation deliver measurable health benefits. While sugar taxes can influence prices, purchases, and product composition, evidence of lasting improvements in obesity, diabetes, and cardiovascular health remains limited. Intermediate outcomes should not be confused with demonstrated health benefits. Reviewed studies estimate reductions of 2.

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates5.11.2026 13:00:00 EET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiated capabilities in R&D, manufacturing, and commercialization.” (Amounts in thousands of U.S. dollars and unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 % Change 2026 2025 % Change Net product revenues $ 1,855,057 $ 1,395,013 33 % $ 5,022,180 $

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye